Stock ALACT ACTICOR BIOTECH SAS
Add to a list
To use this feature you must be a member
Log inSign up

Acticor Biotech SAS Stock

Equities

ALACT

FR0014005OJ5

Biotechnology & Medical Research

End-of-day quote Euronext Paris
Other stock markets
 06:00:00 2024-05-14 pm EDT 		5-day change 1st Jan Change
1.14 EUR +35.71% Intraday chart for Acticor Biotech SAS +35.71% -60.69%
May. 15 Acticor: 'new perspectives' in stroke treatment CF
May. 15 Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024 CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2023 * - Sales 2024 * - Capitalization 14.97M 16.27M
Net income 2023 * -15M -16.3M Net income 2024 * -13M -14.13M EV / Sales 2023 * -
Net Debt 2023 * 5.2M 5.65M Net Debt 2024 * 10.8M 11.74M EV / Sales 2024 * -
P/E ratio 2023 *
-0.97 x
P/E ratio 2024 *
-1.34 x
Employees 29
Yield 2023 *
-
Yield 2024 *
-
Free-Float 100%
More Fundamentals * Assessed data

Chart Acticor Biotech SAS

Dynamic Chart

Latest news about Acticor Biotech SAS

Acticor: 'new perspectives' in stroke treatment CF
Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024 CI
Acticor Biotech SAS Announces Postponement in Publication of 2023 Annual Results CI
Acticor Biotech: rebound from the previous day's tumble CF
Acticor Biotech: Phase 2/3 study fails CF
Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment CI
Acticor Biotech: phase 2/3 results expected in May CF
Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024 CI
Acticor Biotech: falls after capital increase CF
Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development MT
The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attack CI
Acticor: 'we are delighted to observe the market's reaction'. CF
Acticor Biotech continues to soar, hopes for stroke treatment CF
Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal CI
Acticor: capital increase at a significant discount CF
More news

Press releases Acticor Biotech SAS

ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024 BU
ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023 BU
ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment BU
Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024 BU
Acticor Biotech Completes a Capital Increase for a Total Gross Amount of 8 Million Euros BU
More press releases

News in other languages on Acticor Biotech SAS

Acticor : de 'nouvelles perspectives' dans les AVC
ACTICOR BIOTECH : Présentation des principaux résultats de l’étude de phase 2/3 ACTISAVE dans le traitement de l’AVC lors de l’ESOC 2024
Acticor Biotech : reporte la publication de ses résultats
ACTICOR BIOTECH : Report de la publication des résultats annuels et du Document d’enregistrement universel 2023
DBT : Air France KLM, Capgemini, Imerys, Vetoquinol... les valeurs à suivre demain à la Bourse de Paris
More news

Quotes and Performance

1 day+35.71%
1 week+35.71%
Current month+192.31%
1 month-70.00%
3 months-72.86%
6 months-70.00%
Current year-60.69%
More quotes

Highs and lows

1 week
0.65
Extreme 0.646
1.24
1 month
0.27
Extreme 0.27
4.21
Current year
0.27
Extreme 0.27
5.32
1 year
0.27
Extreme 0.27
6.20
3 years
0.27
Extreme 0.27
11.00
5 years
0.27
Extreme 0.27
11.00
10 years
0.27
Extreme 0.27
11.00
More quotes

Managers and Directors - Acticor Biotech SAS

Managers TitleAgeSince
Gilles Avenard FOU
 Founder - 13-11-25
Eric Cohen DFI
 Director of Finance/CFO - -
Adeline Meilhoc CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Gilles Avenard FOU
 Founder - 13-11-25
Catherine Boule BRD
 Director/Board Member - -
Alain Munoz CHM
 Chairman 75 21-06-14
More insiders

Quotes

Date Price Change Volume
24-05-15 1.14 +35.71% 569,528
24-05-14 0.84 +10.53% 125,760
24-05-13 0.76 -5.24% 110,364
24-05-10 0.802 +6.08% 247,643
24-05-09 0.756 -10.00% 255,225

End-of-day quote Euronext Paris, May 14, 2024

More quotes

Company Profile

Acticor Biotech is specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II/III clinical development (Glenzocimab).
Sector
Biotechnology & Medical Research
Calendar
2024-06-20 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
1.14 EUR
Average target price
1 EUR
Spread / Average Target
-12.28%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACTICOR BIOTECH SAS Stock Acticor Biotech SAS
-60.69% 16.27M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.52% 113B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.38% 106B
ARGENX SE Stock argenx SE
+0.96% 22.27B
BIONTECH SE Stock BioNTech SE
-12.64% 22.22B
GENMAB A/S Stock Genmab A/S
-5.24% 19.43B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.85% 17.87B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.58% 17.24B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.77% 14.29B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.41% 12.52B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALACT Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW